Safety and tolerability of a bevacizumab biosimilar (Effivia®) in adult Mexican patients with cancer: a multicenter, observational, prospective clinical study

Safety and tolerability of a bevacizumab biosimilar (Effivia®) in adult Mexican patients with cancer: a multicenter, observational, prospective clinical study

IntroductionSafety of biosimilars is of major relevance for patients and medical community. The aim of this study was to evaluate the safety and tolerability of a bevacizumab biosimilar alongside standard chemotherapy in adult patients with cancer. In addition, the impact on patients’ quality-of-lif...

Full description

Saved in:
Bibliographic Details
Main Authors: Alberto Alfonso Pimentel-Rentería, David Francisco Cantú de León, Eliseo Neftalí De la Cruz, David Suárez, Manuel Rodulfo Segura, José Gustavo Núñez, Livan Delgado-Roche
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Drug Discovery
Subjects:
bevacizumab
biosimilar
metastatic cancer
safety
pharmacovigilance
Online Access:https://www.frontiersin.org/articles/10.3389/fddsv.2025.1591991/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items